Beta
ManageSearchChatDiscover
239464

EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY

Article

Last updated: 25 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children. Poor academic readiness for school entry, fine motor skills, and social impairment are more common in preschoolers than healthy controls. Since dopaminergic system dysfunction is connected with numerous neuropsychological diseases, including ADHD, antipsychotic drugs are used for the treatment of ADHD. Considering the importance of ADHD treatment in preschoolers and the fact that psychostimulant drugs are less effective in preschoolers and have more adverse effects, this study is conducted to compare the safety and efficacy of risperidone and aripiprazole in the treatment of ADHD. Fifty-five 3-6-year-old children diagnosed with ADHD were randomized to a 12-week trial of treatment with risperidone or aripiprazole1. The assessment was performed by Parent ADHD-RS, Strengths and Difficulties Questionnaire (SDQ), Children's Global Assessment Scale (CGAS) before treatment, and weeks 2, 4, 6, and 12 of treatment. The study showed that the ADHD-RS score of both groups was significantly reduced after starting the treatment. After the 12th week, the score of aripiprazole's group was significantly less than the score of risperidone's group (p-value = 0.019). In addition, the CGAS scores and the total SDQ score improved for both groups without any statistically significant difference between them. Both risperidone and aripiprazole are effective in the treatment of ADHD among preschool-aged children. Both drugs are well-tolerated, significantly reduce the ADHD-RS score and the total SDQ score and improve the CGAS score.

DOI

10.21608/bfsa.2022.239464

Keywords

attention-deficit hyperactivity disorder, aripiprazole, risperidone, clinical trial

Authors

First Name

Firoozeh

Last Name

Dreakhshanpour

MiddleName

-

Affiliation

Associated Professor of Psychiatry, Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran

Email

-

City

-

Orcid

-

First Name

Anahita

Last Name

Deylamsalehi

MiddleName

-

Affiliation

MPH Student ,San Jose State University , California,USA

Email

anahitylamsaleh@gmail.com

City

-

Orcid

-

First Name

Seyed

Last Name

Moghadda

MiddleName

Shahab Jazayeri

Affiliation

Internal Medicine, Saint Mary´s Hospital, Waterbury, Connecticut

Email

-

City

-

Orcid

-

First Name

Najmeh

Last Name

Shahini

MiddleName

-

Affiliation

Assistant Professor of Psychiatry, Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran

Email

najmehshahini@chmail.ir

City

-

Orcid

-

Volume

45

Article Issue

1

Related Issue

34403

Issue Date

2022-06-01

Receive Date

2021-10-11

Publish Date

2022-06-01

Page Start

281

Page End

288

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 45_Issue 1_Pages 281-288.pdf

PDF . 772.4kB

Link

https://bpsa.journals.ekb.eg/article_239464.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=239464

Order

22

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY

Details

Type

Article

Created At

22 Jan 2023